Association between the interleukin-6 promoter polymorphism -174G/C and serum lipoprotein(a) concentrations in humans

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Berthold, Heiner K ^a   Laudes, Matthias ^b,c   Krone, Wilhelm ^b   Gouni Berthold, Ioanna ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOSINE; GUANINE; INTERLEUKIN 6; LIPOPROTEIN; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGE; ARTICLE; BODY MASS; CIGARETTE SMOKING; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; HYPERTENSION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PROMOTER REGION; RISK ASSESSMENT; SEX DIFFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; AGED; BLOOD; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED;

AGED; FEMALE; GENOTYPE; HUMANS; INTERLEUKIN-6; LIPOPROTEIN(A); MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC;

EID: 80052826506     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024719     Document Type: Article

References (54)

1. Utermann G, (2001) Lipoprotein(a). In: Scriver C, Beaudet A, Sly W, Valle D, editors. The metabolic and molecular bases of inherited disease New York McGraw-Hill Professional pp. 2753-2787.
2. Nordestgaard BG, Chapman MJ, Ray K, Boren J, Andreotti F, et al. (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 31: 2844-2853 ehq386 [pii];10.1093/eurheartj/ehq386 [doi].
3. Joshi PH, Krivitsky E, Qian Z, Vazquez G, Voros S, et al. (2010) Do We Know When and How to Lower Lipoprotein(a)? Curr Treat Options Cardiovasc Med 12: 396-407 10.1007/s11936-010-0077-6 [doi].
4. Carlson LA, Hamsten A, Asplund A, (1989) Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 226: 271-276.
5. Cannon CP, Shah S, Dansky HM, Davidson M, Brinton EA, et al. (2010) Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 363: 2406-2415 10.1056/NEJMoa1009744 [doi].
6. Ladenson PW, Kristensen JD, Ridgway EC, Olsson AG, Carlsson B, et al. (2010) Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia. N Engl J Med 362: 906-916 362/10/906 [pii];10.1056/NEJMoa0905633 [doi].
7. Raal FJ, Santos RD, Blom DJ, Marais AD, Charng MJ, et al. (2010) Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 375: 998-1006 S0140-6736(10)60284-X [pii];10.1016/S0140-6736(10)60284-X [doi].
8. Schultz O, Oberhauser F, Saech J, Rubbert-Roth A, Hahn M, et al. (2010) Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One 5: e14328 10.1371/journal.pone.0014328 [doi].
9. Hamid YH, Rose CS, Urhammer SA, Glumer C, Nolsoe R, et al. (2005) Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes. Diabetologia 48: 251-260 10.1007/s00125-004-1623-0 [doi].
10. Yeh KY, Li YY, Hsieh LL, Chen JR, Tang RP, (2010) The -174 G/C polymorphism in interleukin-6 (IL-6) promoter region is associated with serum IL-6 and carcinoembryonic antigen levels in patients with colorectal cancers in Taiwan. J Clin Immunol 30: 53-59 10.1007/s10875-009-9324-6 [doi].
11. Pereira DS, Garcia DM, Narciso FM, Santos ML, Dias JM, et al. (2011) Effects of 174 G/C polymorphism in the promoter region of the interleukin-6 gene on plasma IL-6 levels and muscle strength in elderly women. Braz J Med Biol Res 44: 123-129 S0100-879X2010007500152 [pii].
12. Olivieri F, Bonafe M, Cavallone L, Giovagnetti S, Marchegiani F, et al. (2002) The -174 C/G locus affects in vitro/in vivo IL-6 production during aging. Exp Gerontol 37: 309-314 S0531556501001978 [pii].
13. Gouni-Berthold I, Giannakidou E, Muller-Wieland D, Faust M, Kotzka J, et al. (2005) Peroxisome proliferator-activated receptor-gamma2 Pro12Ala and endothelial nitric oxide synthase-4a/b gene polymorphisms are not associated with hypertension in diabetes mellitus type 2. J Hypertens 23: 301-308.
14. Gouni-Berthold I, Giannakidou E, Faust M, Berthold HK, Krone W, (2005) The peroxisome proliferator-activated receptor delta +294T/C polymorphism in relation to lipoprotein metabolism in patients with diabetes mellitus type 2 and in non-diabetic controls. Atherosclerosis 183: 336-341 S0021-9150(05)00225-X [pii];10.1016/j.atherosclerosis.2005.03.016 [doi].
15. Siekmeier R, März W, Scharnagl H, Nauck M, Mayer H, et al. (1996) Bestimmung von Lipoprotein(a): Vergleich eines neuen latexverstärkten immunoturbidimetrischen Assay mit einem immunoradiometrischen Assay. Journal of Laboratory Medicine 20: 294-298.
16. Libra M, Signorelli SS, Bevelacqua Y, Navolanic PM, Bevelacqua V, et al. (2006) Analysis of G(-174)C IL-6 polymorphism and plasma concentrations of inflammatory markers in patients with type 2 diabetes and peripheral arterial disease. J Clin Pathol 59: 211-215 59/2/211 [pii];10.1136/jcp.2004.025452 [doi].
17. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG, (2009) Genetically elevated lipoprotein(a) and increased risk of myocardial infarction. JAMA 301: 2331-2339 301/22/2331 [pii];10.1001/jama.2009.801 [doi].
18. Clarke R, Peden JF, Hopewell JC, Kyriakou T, Goel A, et al. (2009) Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Engl J Med 361: 2518-2528 361/26/2518 [pii];10.1056/NEJMoa0902604 [doi].
19. Erqou S, Kaptoge S, Perry PL, Di AE, Thompson A, et al. (2009) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 302: 412-423 302/4/412 [pii];10.1001/jama.2009.1063 [doi].
20. Libby P, Ridker PM, Hansson GK, (2009) Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol 54: 2129-2138 S0735-1097(09)03006-X [pii];10.1016/j.jacc.2009.09.009 [doi].
21. Tan J, Hua Q, Li J, Fan Z, (2009) Prognostic value of interleukin-6 during a 3-year follow-up in patients with acute ST-segment elevation myocardial infarction. Heart Vessels 24: 329-334 10.1007/s00380-008-1128-8 [doi].
22. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, et al. (2003) Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes 52: 812-817.
23. Huth C, Heid IM, Vollmert C, Gieger C, Grallert H, et al. (2006) IL6 gene promoter polymorphisms and type 2 diabetes: joint analysis of individual participants' data from 21 studies. Diabetes 55: 2915-2921 55/10/2915 [pii];10.2337/db06-0600 [doi].
24. Kim KI, Lee JH, Chang HJ, Cho YS, Youn TJ, et al. (2008) Association between blood pressure variability and inflammatory marker in hypertensive patients. Circ J 72: 293-298 JST.JSTAGE/circj/72.293 [pii].
25. Jonkers IJ, Mohrschladt MF, Westendorp RG, van der Laarse A, Smelt AH, (2002) Severe hypertriglyceridemia with insulin resistance is associated with systemic inflammation: reversal with bezafibrate therapy in a randomized controlled trial. Am J Med 112: 275-280 S0002934301011238 [pii].
26. Kamimura D, Ishihara K, Hirano T, (2003) IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol 149: 1-38 10.1007/s10254-003-0012-2 [doi].
27. Rose-John S, Scheller J, Elson G, Jones SA, (2006) Interleukin-6 biology is coordinated by membrane-bound and soluble receptors: role in inflammation and cancer. J Leukoc Biol 80: 227-236 jlb.1105674 [pii];10.1189/jlb.1105674 [doi].
28. Rieusset J, Bouzakri K, Chevillotte E, Ricard N, Jacquet D, et al. (2004) Suppressor of cytokine signaling 3 expression and insulin resistance in skeletal muscle of obese and type 2 diabetic patients. Diabetes 53: 2232-2241 53/9/2232 [pii].
29. Wypasek E, Undas A, Sniezek-Maciejewska M, Kapelak B, Plicner D, et al. (2010) The increased plasma C-reactive protein and interleukin-6 levels in patients undergoing coronary artery bypass grafting surgery are associated with the interleukin-6-174G&C gene polymorphism. Ann Clin Biochem 47: 343-349 47/4/343 [pii];10.1258/acb.2010.090305 [doi].
30. Fernandez-Real JM, Broch M, Vendrell J, Richart C, Ricart W, (2000) Interleukin-6 gene polymorphism and lipid abnormalities in healthy subjects. J Clin Endocrinol Metab 85: 1334-1339.
31. Haddy N, Sass C, Maumus S, Marie B, Droesch S, et al. (2005) Biological variations, genetic polymorphisms and familial resemblance of TNF-alpha and IL-6 concentrations: STANISLAS cohort. Eur J Hum Genet 13: 109-117 5201294 [pii];10.1038/sj.ejhg.5201294 [doi].
32. Oberbach A, Lehmann S, Kirsch K, Krist J, Sonnabend M, et al. (2008) Long-term exercise training decreases interleukin-6 (IL-6) serum levels in subjects with impaired glucose tolerance: effect of the -174G/C variant in IL-6 gene. Eur J Endocrinol 159: 129-136 EJE-08-0220 [pii];10.1530/EJE-08-0220 [doi].
33. Jones KG, Brull DJ, Brown LC, Sian M, Greenhalgh RM, et al. (2001) Interleukin-6 (IL-6) and the prognosis of abdominal aortic aneurysms. Circulation 103: 2260-2265.
34. Fishman D, Faulds G, Jeffery R, Mohamed-Ali V, Yudkin JS, et al. (1998) The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest 102: 1369-1376 10.1172/JCI2629 [doi].
35. Sanders J, Hawe E, Brull DJ, Hubbart C, Lowe GD, et al. (2009) Higher IL-6 levels but not IL6 -174G&C or -572G&C genotype are associated with post-operative complication following coronary artery bypass graft (CABG) surgery. Atherosclerosis 204: 196-201 S0021-9150(08)00615-1 [pii];10.1016/j.atherosclerosis.2008.08.032 [doi].
36. Margaglione M, Bossone A, Cappucci G, Colaizzo D, Grandone E, et al. (2001) The effect of the interleukin-6 c/g-174 polymorphism and circulating interleukin-6 on fibrinogen plasma levels. Haematologica 86: 199-204.
37. Rauramaa R, Vaisanen SB, Luong LA, Schmidt-Trucksass A, Penttila IM, et al. (2000) Stromelysin-1 and interleukin-6 gene promoter polymorphisms are determinants of asymptomatic carotid artery atherosclerosis. Arterioscler Thromb Vasc Biol 20: 2657-2662.
38. Vickers MA, Green FR, Terry C, Mayosi BM, Julier C, et al. (2002) Genotype at a promoter polymorphism of the interleukin-6 gene is associated with baseline levels of plasma C-reactive protein. Cardiovasc Res 53: 1029-1034 S000863630100534X [pii].
39. Berg KK, Madsen HO, Garred P, Wiseth R, Gunnes S, et al. (2009) The additive contribution from inflammatory genetic markers on the severity of cardiovascular disease. Scand J Immunol 69: 36-42 SJI2187 [pii];10.1111/j.1365-3083.2008.02187.x [doi].
40. Revilla M, Obach V, Cervera A, Davalos A, Castillo J, et al. (2002) A -174G/C polymorphism of the interleukin-6 gene in patients with lacunar infarction. Neurosci Lett 324: 29-32 S0304394002001696 [pii].
41. Losito A, Kalidas K, Santoni S, Jeffery S, (2003) Association of interleukin-6 -174G/C promoter polymorphism with hypertension and left ventricular hypertrophy in dialysis patients. Kidney Int 64: 616-622 kid119 [pii];10.1046/j.1523-1755.2003.00119.x [doi].
42. Kristiansen OP, Mandrup-Poulsen T, (2005) Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes 54 (Suppl 2): S114-S124 54/suppl_2/S114 [pii].
43. Hurme M, Lehtimaki T, Jylha M, Karhunen PJ, Hervonen A, (2005) Interleukin-6 -174G/C polymorphism and longevity: a follow-up study. Mech Ageing Dev 126: 417-418 S0047-6374(04)00255-6 [pii];10.1016/j.mad.2004.10.001 [doi].
44. Yun KA, Lee W, Min WK, Chun S, Lee YW, et al. (2004) Discrepancy of interleukin-6 levels between end-stage renal disease patients and patients with acute-phase response with increased lipoprotein(a) concentrations. Scand J Clin Lab Invest 64: 223-228.
45. Qi L, Zhang C, van Dam RM, Hu FB, (2007) Interleukin-6 genetic variability and adiposity: associations in two prospective cohorts and systematic review in 26,944 individuals. J Clin Endocrinol Metab 92: 3618-3625 jc.2007-0877 [pii];10.1210/jc.2007-0877 [doi].
46. Nonogaki K, Fuller GM, Fuentes NL, Moser AH, Staprans I, et al. (1995) Interleukin-6 stimulates hepatic triglyceride secretion in rats. Endocrinology 136: 2143-2149.
47. Sparks JD, Cianci J, Jokinen J, Chen LS, Sparks CE, (2010) Interleukin-6 mediates hepatic hypersecretion of apolipoprotein B. Am J Physiol Gastrointest Liver Physiol 299: G980-G989 ajpgi.00080.2010 [pii];10.1152/ajpgi.00080.2010 [doi].
48. Henningsson S, Hakansson A, Westberg L, Baghaei F, Rosmond R, et al. (2006) Interleukin-6 gene polymorphism -174G/C influences plasma lipid levels in women. Obesity (Silver Spring) 14: 1868-1873 14/11/1868 [pii];10.1038/oby.2006.216 [doi].
49. Mora S, Kamstrup PR, Rifai N, Nordestgaard BG, Buring JE, et al. (2010) Lipoprotein(a) and risk of type 2 diabetes. Clin Chem 56: 1252-1260 clinchem.2010.146779 [pii];10.1373/clinchem.2010.146779 [doi].
50. Boyer H, de Gennes JL, Truffert J, Chatellier G, Dairou F, et al. (1990) Lp(a) levels in different types of dyslipidemia in the French population. Atherosclerosis 85: 61-69.
51. Candido AP, Ferreira S, Lima AA, de Carvalho Nicolato RL, de Freitas SN, et al. (2007) Lipoprotein(a) as a risk factor associated with ischemic heart disease: Ouro Preto Study. Atherosclerosis 191: 454-459 S0021-9150(06)00240-1 [pii];10.1016/j.atherosclerosis.2006.04.031 [doi].
52. Chien KL, Lee YT, Sung FC, Su TC, Hsu HC, et al. (1999) Lipoprotein (a) level in the population in Taiwan: relationship to sociodemographic and atherosclerotic risk factors. Atherosclerosis 143: 267-273 S0021915098002986 [pii].
53. Mora S, Lee IM, Buring JE, Ridker PM, (2006) Association of physical activity and body mass index with novel and traditional cardiovascular biomarkers in women. JAMA 295: 1412-1419 295/12/1412 [pii];10.1001/jama.295.12.1412 [doi].
54. Gouni-Berthold I, Berthold HK, (2011) Lipoprotein(a): Current Perspectives. Curr Vasc Pharmacol BSP/CVP/E-Pub/0000160 [pii].